Voyager Acquisition Corp./Cayman Islands Business Summary

Voyager Acquisition Corp. (VACH) is a Cayman Islands-exempted special purpose acquisition company (SPAC) that generates revenue through the strategic deployment of trust capital into high-growth business combinations. As of February 2026, the company is in the final stages of a definitive merger with Veraxa Biotech, a leader in antibody-drug conjugates (ADCs) and protein engineering, in a transaction valued at approximately $1.35 billion. VACH operates primarily within the healthcare and biotechnology segments, focusing on identifying targets with proprietary drug-discovery platforms and scalable clinical pipelines. In the competitive landscape of healthcare-focused shell companies, VACH competes directly with Ares Acquisition Corporation II, Colombier Acquisition Corp, and HCM II Acquisition Corp. Relative to these peers, VACH distinguishes itself through its advanced deal progression and its pivot toward the high-valuation ADC sector, positioning it as a late-stage vehicle for institutional investors seeking exposure to precision oncology. The leadership team is anchored by President and CEO Adeel Rouf Ennis, a seasoned financier who previously served as CFO for the SPAC that successfully took Rubicon Technologies public. Financial operations are led by CFO Alex R. Rogers, a Principal at Blue Ox Healthcare Partners with over 15 years of alternative investment experience at firms such as First Reserve and MVision. The board is chaired by Warren Hosseinion, M.D., the co-founder and former CEO of Apollo Medical Holdings (NASDAQ: AMEH), who brings extensive clinical and executive expertise in scaling healthcare services. Other notable board members include Oded Levy, Managing Partner at Blue Ox Healthcare Partners, and Jonathan Intrater, a Managing Director at Ladenburg Thalmann. This leadership pedigree provides VACH with a robust network of proprietary deal flow and deep institutional credibility within the global life sciences market.